TG THERAPEUTICS, INC.
No SEC Form 4 filings for $TGTX in the last 30 days.
See all $TGTX insider activity →TG Therapeutics (TGTX) shares surged 85% YTD after a Betaville report suggested a potential takeover by a U.S. biopharma company. TGTX reported Q2 revenue of $227.7M for BRIUMVI, up 64% YoY, and raised its 2026 revenue target to $950M. Analysts maintain a 'Moderate Buy' rating with a $64 price target, implying 17% upside.
TG Therapeutics (TGTX) shares rose 11.9% as investors reassessed its growth outlook. The company raised 2026 revenue guidance for BRIUMVI and reported progress in its simplified dosing program. It also expects data from a Phase 3 trial of subcutaneous BRIUMVI by early 2027. Institutional investors have recently increased their positions in the stock.
US equities show sharp divergence midday. Robinhood (HOOD) +13.28%, Moderna (MRNA) +12.01%, Hut 8 (HUT) -9.51%, Alibaba (BABA) -7.01%. Other movers include TG Therapeutics (TGTX), USA Rare Earth (USAR), Infleqtion (INFQ), OSI Systems (OSIS), Telix Pharmaceuticals (TLX), Seabridge Gold (SA).
Over the past 7 days, alphai's AI scored 4 news stories mentioning TGTX (TG THERAPEUTICS, INC.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent TGTX coverage spans earnings, market movers and financial news.
Takeover rumor drove a sharp price surge.
Guidance raise and trial data suggest stronger near-term sales and potential label expansion, supporting further upside.
Midday rally with no disclosed catalyst.
Short-term price rally driven by lower entry point and improved guidance.
Higher 2026 revenue guidance strengthens the near-term bull case for BRIUMVI commercial execution, but margin and payer-risk concerns remain.
alphai scores every news story that mentions TGTX with an AI model for sentiment and relevance, and aggregates insider trades from TG THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TG Therapeutics (TGTX) shares surged 85% YTD after a Betaville report suggested a potential takeover by a U.S. biopharma company. TGTX reported Q2 revenue of $227.7M for BRIUMVI, up 64% YoY, and raised its 2026 revenue target to $950M. Analysts maintain a 'Moderate Buy' rating with a $64 price target, implying 17% upside.
2 min readTG Therapeutics (TGTX) shares rose 11.9% as investors reassessed its growth outlook. The company raised 2026 revenue guidance for BRIUMVI and reported progress in its simplified dosing program. It also expects data from a Phase 3 trial of subcutaneous BRIUMVI by early 2027. Institutional investors have recently increased their positions in the stock.
2 min readUS equities show sharp divergence midday. Robinhood (HOOD) +13.28%, Moderna (MRNA) +12.01%, Hut 8 (HUT) -9.51%, Alibaba (BABA) -7.01%. Other movers include TG Therapeutics (TGTX), USA Rare Earth (USAR), Infleqtion (INFQ), OSI Systems (OSIS), Telix Pharmaceuticals (TLX), Seabridge Gold (SA).
2 min readTG Therapeutics (TGTX) stock rose 5.9% to $53.55, recovering from a post-earnings selloff. Q2 revenue was $240M, up 70% YoY, and the company raised its 2026 revenue target to $950M. Despite an EPS miss, analysts remain bullish with price targets above current levels. The broader market's positive tone also supported the rally.
1 min readSimply Wall St reports TG Therapeutics (TGTX) posted Q2 2026 revenue of $240.34 million versus $141.15 million a year earlier, while net income fell to $7.78 million from $28.19 million. The company raised full-year 2026 total global revenue guidance to about $950 million, citing improved commercial trajectory.
4 min readTG Therapeutics (TGTX) reported Q2 2026 results with higher revenue and lower net income, and raised full-year revenue guidance to about $950 million, according to the company. The stock last traded at $47.94, framed by Simply Wall St as modestly undervalued versus a $51.71 fair value, largely tied to BRIUMVI ramp-up and market access.
4 min readTG Therapeutics said Q2 2026 results reflected record new patient starts and broader physician adoption of BRIUMVI. The company raised full-year 2026 U.S. BRIUMVI net revenue guidance to $890 million to $905 million and expects about $950 million global revenue. It reported $55 million in R&D charges tied to subcutaneous manufacturing and cited Phase III data for a 600 mg single-infusion schedule.
5 min readTG Therapeutics (TGTX) shares fell about 11% the day after earnings, as profit declined despite growth tied to BRIUMVI. The company reported Q2 2026 revenue of about $240.3M (up from $141.1M) and BRIUMVI revenue of about $228M, but net income fell to $7.8M and EPS to just over $0.05. Management cited manufacturing charges.
4 min readTG Therapeutics Inc. (TGTX) reported Q2 net income of $7.8 million, or 5 cents per share, below Wall Street expectations of 41 cents per share, according to Zacks. Revenue was $240.3 million, above the $230.9 million forecast. The company expects full-year revenue of $950 million.
3 min readTG Therapeutics (TGTX.OB) reported Q2 results. Net income fell to $7.78 million, or $0.05 per share, from $28.19 million, or $0.17 per share, a year earlier. Revenue rose 70.3% to $240.33 million from $141.15 million. Full-year revenue guidance is $890 million to $905 million.
2 min read
